**Section:** 8. Immunomodulators and antineoplastics  >  8.2. Antineoplastics and supportive medicines  >  8.2.3. Immunomodulators

---

**Indication**

| Acquired neutropaenia | ICD11 code: 4B00.01 |

**INN**

Filgrastim

**Medicine type**

Biological agent

**List type**

Complementary (EML) (EMLc)

**Additional notes**

Including quality-assured biosimilars.

**Formulations**

Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

**EML status history**

First added in 2015 (TRS 994)

**Sex**

All

**Age**

Also recommended for children

**Therapeutic alternatives**

The recommendation is for this specific medicine

**Patent information**

Patents have expired in most jurisdictions

Read more about patents.

**Tags**

- Cancer
- Biological

---

**Summary of evidence and Expert Committee recommendations**

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, filgrastim, a granulocyte colony stimulating factor, was added to the complementary list of the EML and EMLc for use in the following indications:

- primary prophylaxis in patients at high risk for developing febrile neutropenia associated with myelotoxic chemotherapy;
- secondary prophylaxis for patients who have experienced neutropenia following prior myelotoxic chemotherapy;
- to facilitate administration of dose dense chemotherapy regimens.

The relevant extract from TRS994 regarding the Expert Committee's consideration of G-CSF is attached.

---

**Wikipedia**

Filgrastim

**DrugBank**

Filgrastim